If you have an article you'd like to submit, please contact [email protected].
Canada's patent 'utiity' regime on trial
The Supreme Court's decision to hear AstraZeneca's appeal and this month's NAFTA hearings on an Eli Lilly complaint shine a light on Canada's unusual legal approach to invalidating patents, writes Adrienne Blanchard on the MLI website.
Dodged bullet or missed opportunity with CHEO settlement?
While there was certainly a win on the costs of genetic testing, the long-term effects of Transgenomic's departure from the Canadian market, and the missed chance to clarify Canada's patent laws, are less clear. Richard C. Owens delves into the issue for the MLI website.
Stop the TPP-IP media pile-on
It has become fashionable to declare the Trans-Pacific Partnership intellectual property provisions a disaster for innovation in Canada, writes Richard C. Owens for the MLI website. But that doesn't make it right.
Other IP news from around the web...
A New Zealand study on the cost of extending the terms of copyright by 20 years is a flimsy basis for claiming that the Trans-Pacific Partnership will hurt Canada,writes lawyer Barry Sookman.
How will the Canada-European Free Trade Agreement affect Canadian IP law? Patrick Cashin and Scott E. Foster, lawyers with Gowling WLG, offer their thoughts.